Latest Esomeprazole Stories
SEATTLE, Aug. 10, 2011 /PRNewswire/ -- The following statement is being issued by GCG Inc., Notice Administrator regarding the Commonwealth Care Alliance v. AstraZeneca Pharmaceuticals L.P., Docket No.
In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years.
Without GI protection, 87 per cent of NSAID users are at increased risk of developing GI complications To view the Social Media Release, click here: http://smr.newswire.ca/en/vimovo/health-canada-approves-vimovo MISSISSAUGA, ON, April 27 /PRNewswire/ - AstraZeneca Canada Inc.
HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court. Filed in the U.S.
NEW ORLEANS, April 5, 2011 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate).
The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleepâ€”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleepâ€”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.
Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S.
The results of several studies released on Monday are suggesting that certain heartburn medicines may be doing more harm than good.
WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S.
ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.